No Data
12 Health Care Stocks Moving In Thursday's After-Market Session
Palisade Bio Shares Are Trading Higher After the Company Announced the Presentation of Data From Two Studios Showing Ex Vivo Bioactivation of PALI-2108 in the Treatment of Ulcerative Colitis.
Palisade Bio Files for Public Offering of Shares, Warrants
Palisade Bio Announces Abstract Accepted for Presentation at the American College of Gastroenterology's (ACG) 2024 Annual Scientific Meeting
Maxim Group Maintains Palisade Bio(PALI.US) With Buy Rating, Maintains Target Price $22.5
Buy Rating for Palisade Bio Amid Novel UC Treatment Potential and Health Canada Trial Approval
No Data
No Data